684286-94-0Relevant academic research and scientific papers
Design, synthesis, and biological evaluation of novel tricyclic HIV-1 integrase inhibitors by modification of its pyridine ring
Metobo, Sammy E.,Jin, Haolun,Tsiang, Manuel,Kim, Choung U.
, p. 3985 - 3988 (2007/10/03)
This communication details both the syntheses and biological evaluation of a novel class of HIV-1 integrase inhibitors. When the quinoline moiety is replaced with the quinoxoline moiety, the antiviral activity is significantly compromised. Similarly, intr
PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS
-
Page/Page column 537-538, (2010/02/15)
Novel HIV integrase inhibitor compounds having at least one phosphonate group, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.
PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS
-
Page 299;300, (2008/06/13)
Tricyclic compounds according to the structure below, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed. Formula (I). Al and A2 are moieties forming a five, six, or seven membered ring. L is a bond or a linker connecting a ring atom of Ar to N. X is O, S, or substituted nitrogen. Ar is aryl or heteroaryl. Q is N, +NR, or CR4. The aryl carbons may be independently substituted with substituents other than hydrogen. The compounds may include prodrug moieties covalently attached at any site.
